Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingObservational

Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

NCT ID: NCT01166009Sponsor: Center for International Blood and Marrow Transplant ResearchLast updated: 2025-08-12

Summary

The primary purpose of the Research Database is to have a comprehensive source of observational data that can be used to study HSC transplantation and cellular therapies. A secondary purpose of the Research Database is to have a comprehensive source of data to study marrow toxic injuries. Objectives: To learn more about what makes stem cell transplants and cellular therapies work well such as: * Determine how well recipients recover from their transplants or cellular therapy; * Determine how recovery after a transplant or cellular therapy can be improved; * Determine how a donor's or recipient's genetics impact recipient recovery after a transplant or cellular therapy; * Determine how access to transplant or cellular therapy for different groups of patients can be improved; * Determine how well donors recover from the collection procedures.

Outcome measures

Primary

  • A Comprehensive Source of Observational Data to assess Stem Cell Transplant

    A primary outcome is to have a comprehensive source of stem cell transplant data that can be used to assess topics such as: * Recipient Recover time * How recovery after transplant and other cellular therapies can be improved * Long term outcomes after transplantation and other cellular therapies * How well donors recover from collection procedure

    Time frame: Anually - on average

Secondary

  • A Comprehensive Source of Data for Marrow Toxic Injuries

    Time frame: anually- on average

  • Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients with Medicare Coverage (17-CMS-SCD)

    Time frame: annually - on average

  • Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients with Medicare Coverage (10CMSMDS-1)

    Time frame: annually - on average

Eligibility criteria

Sex: AllAge: All agesHealthy volunteers: No
Eligibility to Participate in the Research Database Recipient Eligibility Criteria: * Any recipient of an unrelated or related donor or autologous HSC transplant in a CIBMTR center is eligible to participate in the Research Database. This includes adults with and without decision making capacity, and children. Individual with Marrow Toxic Injury Eligibility Criteria: * Any individual who is treated for a marrow toxic injury at a center participating in the NMDP's Radiation Injury Transplant Network (RITN) is eligible to participate in the Research Database. This includes adults with and without decision making capacity, and children. Eligible individuals may have received supportive care only, growth factor support, HSC transplant or other appropriate medical treatment for marrow toxic injury. Treatments applied are at the discretion of the care facility, and are not determined by the NMDP or CIBMTR. Unrelated Donor Eligibility Criteria: * All donors registered on the NMDP Registry who have been requested to donate a product for a recipient are eligible to participate in the Research Database. * All maternal cord blood donors are enrolled in the NMDP Cord Blood Bank Investigational New Drug (IND) protocol, and sign an informed consent document specific to that protocol. Data collected as part of the Cord Blood Bank protocol are included in the Research Database.

Study locations (2)

Center for International Blood and Marrow Transplant Research

Minneapolis, Minnesota, 55413

Recruiting
Brandan Butler · Contact

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226

Recruiting
Brandan Butler · Contact

References

  • Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, Champlin R, Nishihori T, Confer D, Gajewski J, Farnia S, Greenberg P, Warlick E, Weisdorf D, Saber W, Horowitz MM, Rizzo JD. Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. JAMA Oncol. 2020 Apr 1;6(4):486-493. doi: 10.1001/jamaoncol.2019.5140.(PubMed)